Cardiovascular Outcomes in Trials of New Antidiabetic Drug Classes

Type 2 diabetes is among the most prevalent chronic diseases worldwide and the prevention of associated cardiovascular complications is an important treatment goal. Sodium–glucose co-transporter 2 (SGLT2) inhibitors, glucagon-like peptide 1 (GLP-1) receptor agonists and dipeptidyl peptidase-4 (DPP-4...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Chris Wai Hang Lo, Yue Fei, Bernard Man Yung Cheung
Formato:	article
Lenguaje:	EN
Publicado:	Radcliffe Medical Media 2021
Materias:	Diseases of the circulatory (Cardiovascular) system RC666-701
Acceso en línea:	https://doaj.org/article/5e0a92134d884fb9b6a7f7318868e0c3
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:5e0a92134d884fb9b6a7f7318868e0c3
record_format	dspace
spelling	oai:doaj.org-article:5e0a92134d884fb9b6a7f7318868e0c32021-12-04T16:04:01ZCardiovascular Outcomes in Trials of New Antidiabetic Drug Classes10.15420/cfr.2020.192057-75592057-7540https://doaj.org/article/5e0a92134d884fb9b6a7f7318868e0c32021-03-01T00:00:00Zhttps://www.cfrjournal.com/articleindex/cfr.2020.19https://doaj.org/toc/2057-7540https://doaj.org/toc/2057-7559Type 2 diabetes is among the most prevalent chronic diseases worldwide and the prevention of associated cardiovascular complications is an important treatment goal. Sodium–glucose co-transporter 2 (SGLT2) inhibitors, glucagon-like peptide 1 (GLP-1) receptor agonists and dipeptidyl peptidase-4 (DPP-4) inhibitors are second-line options after metformin, while cardiovascular outcome trials have been conducted to establish the cardiovascular safety of these antidiabetic drug classes. SGLT2 inhibitors have been shown to have the best overall mortality, renal and cardiovascular outcomes. Reduction in hospitalisation for heart failure is particularly consistent. GLP-1 receptor agonists have also showed some benefits, especially in stroke prevention. DPP-4 inhibitors showed neutral effects on cardiovascular outcomes, but may increase the incidence of heart failure. Favourable outcomes observed in trials of SGLT2 inhibitors mean that these should be the preferred second-line option. DPP-4 inhibitors are useful for patients with diabetes at low cardiovascular risk.Chris Wai Hang LoYue FeiBernard Man Yung CheungRadcliffe Medical MediaarticleDiseases of the circulatory (Cardiovascular) systemRC666-701ENCardiac Failure Review , Vol 7, Iss , Pp - (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Diseases of the circulatory (Cardiovascular) system RC666-701
spellingShingle	Diseases of the circulatory (Cardiovascular) system RC666-701 Chris Wai Hang Lo Yue Fei Bernard Man Yung Cheung Cardiovascular Outcomes in Trials of New Antidiabetic Drug Classes
description	Type 2 diabetes is among the most prevalent chronic diseases worldwide and the prevention of associated cardiovascular complications is an important treatment goal. Sodium–glucose co-transporter 2 (SGLT2) inhibitors, glucagon-like peptide 1 (GLP-1) receptor agonists and dipeptidyl peptidase-4 (DPP-4) inhibitors are second-line options after metformin, while cardiovascular outcome trials have been conducted to establish the cardiovascular safety of these antidiabetic drug classes. SGLT2 inhibitors have been shown to have the best overall mortality, renal and cardiovascular outcomes. Reduction in hospitalisation for heart failure is particularly consistent. GLP-1 receptor agonists have also showed some benefits, especially in stroke prevention. DPP-4 inhibitors showed neutral effects on cardiovascular outcomes, but may increase the incidence of heart failure. Favourable outcomes observed in trials of SGLT2 inhibitors mean that these should be the preferred second-line option. DPP-4 inhibitors are useful for patients with diabetes at low cardiovascular risk.
format	article
author	Chris Wai Hang Lo Yue Fei Bernard Man Yung Cheung
author_facet	Chris Wai Hang Lo Yue Fei Bernard Man Yung Cheung
author_sort	Chris Wai Hang Lo
title	Cardiovascular Outcomes in Trials of New Antidiabetic Drug Classes
title_short	Cardiovascular Outcomes in Trials of New Antidiabetic Drug Classes
title_full	Cardiovascular Outcomes in Trials of New Antidiabetic Drug Classes
title_fullStr	Cardiovascular Outcomes in Trials of New Antidiabetic Drug Classes
title_full_unstemmed	Cardiovascular Outcomes in Trials of New Antidiabetic Drug Classes
title_sort	cardiovascular outcomes in trials of new antidiabetic drug classes
publisher	Radcliffe Medical Media
publishDate	2021
url	https://doaj.org/article/5e0a92134d884fb9b6a7f7318868e0c3
work_keys_str_mv	AT chriswaihanglo cardiovascularoutcomesintrialsofnewantidiabeticdrugclasses AT yuefei cardiovascularoutcomesintrialsofnewantidiabeticdrugclasses AT bernardmanyungcheung cardiovascularoutcomesintrialsofnewantidiabeticdrugclasses
_version_	1718372675854794752

Cardiovascular Outcomes in Trials of New Antidiabetic Drug Classes

Ejemplares similares